Report cover image

Fosun International Ltd (00656:HKG) - Strategic SWOT and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends

Publisher Quaintel Research
Published Dec 24, 2025
Length 85 Pages
SKU # QTELR20682527

Description

Report Summary

Fosun International Ltd Strategic SWOT Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends Report is a comprehensive and easily accessible overview of Fosun International Ltd's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.

The report begins with in-depth information about Fosun International Ltd including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.

Next, the report assesses Fosun International Ltd's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Fosun International Ltd's overall strategic standing and supports informed decision-making and strategic planning.

The report also covers Fosun International Ltd's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Fosun International Ltd's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.

Finally, the report includes recent news and deal activities undertaken by Fosun International Ltd enhancing awareness of the company's business trends, growth perspectives, and more.

Key Highlights

Fosun International Ltd is a diversified global investment and industrial group headquartered in Hong Kong, founded in 1992 by Guo Guangchang and several partners. The company operates through multiple core segments, including Health, Happiness, Wealth, and Intelligent Manufacturing, creating a broad portfolio across pharmaceuticals, medical services, tourism, insurance, asset management, and consumer brands. Fosun s strategy focuses on the concept of the global ecosystem, combining industrial operations with investment capabilities to build synergies across markets.In the Health segment, Fosun invests in pharmaceuticals, medical devices, and healthcare services, supporting its mission of delivering accessible medical solutions. Its Happiness segment includes tourism, fashion, and lifestyle brands, highlighted by holdings such as Club Med. The Wealth segment covers insurance, asset management, and financial services, while Intelligent Manufacturing supports advanced materials and high-tech industrial operations.With a strong global footprint spanning Europe, Asia, and the Americas, Fosun aims to drive long-term growth through innovation, globalization, and strategic investments.

Fosun International Ltd in the News:-

2025-08-22 - First Subject Dosed in the US for a Phase 2 International Clinical Trial of Henlius PD-L1 ADC HLX43 for NSCLC

2025-08-07 - Henlius to Initiate a Phase 1 Multicenter Study in US of Its PD-L1 ADC HLX43 for the Treatment of Thymic Carcinoma

2025-07-21 - Club Med appoints Stephane Maquaire as President and CEO

2025-06-24 - Serplulimab Approved in the UK and India for the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

2025-05-29 - Fosun Pharma s Self-Developed Innovative Drug Luvometinib Tablet Approved in China

Scope
  • Tactical Analysis:- Various strategic frameworks to gain insights into a Fosun International Ltd's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
  • Business Strategy:- Contributes to shaping the Fosun International Ltd's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
  • Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
  • Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
  • Competitive Landscape:- An identification of the Fosun International Ltd's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
  • Comprehensive Understanding of the Fosun International Ltd's internal and external factors through SWOT analysis, Financial Analysis, and Competitors Benchmarking.
  • Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
  • Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
  • Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
  • Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
  • Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company Fosun International Ltd:
  • Fosun International Ltd PESTLE Analysis
  • Fosun International Ltd Value Chain Analysis
  • Fosun International Ltd Porter's Five Forces Analysis
  • Fosun International Ltd VRIO Analysis
  • Fosun International Ltd BCG Analysis
  • Fosun International Ltd Segmentation, Targeting and Positioning (STP) Analysis
  • Fosun International Ltd Ansoff Matrix Analysis

Table of Contents

85 Pages
Tables
Charts
Fosun International Ltd - Key Company Facts
Fosun International Ltd - Company Description
Fosun International Ltd - Top Executives
Fosun International Ltd- Head Office & Locations
Head Office - Country
Fosun International Ltd - Products and Services
Products
Services
Fosun International Ltd – Company’s Mission and Vision
Mission
Fosun International Ltd - Corporate Strategy
Fosun International Ltd - Business Description
Health segment
Happiness Segment
Wealth Segment
Intelligent Manufacturing Segment
Fosun International Ltd - ESG Spotlight
Environment
Social
Corporate Governance
Fosun International Ltd - SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Fosun International Ltd - Financial Deep Dive
Share Price Trend - Dec-2024to Dec-2025 (Average Share Closing Price)
Profit and Loss Statement
Summary of Profit and Loss Statement
Balance Sheet
Summary of Balance Sheet
Cash Flow Statement
Summary of Cash Flow Statement
Key Financial Ratio Analysis
Fosun International Ltd - Ratio Charts
Activity Ratio Charts
Growth Ratios Charts
Leverage Ratio Charts
Liquidity Ratio Charts
Profitability Ratio Charts
Competing Players
Snapshot of Competing Players
China Everbright Ltd
Key Company Facts
Company Description
Snapshot of Competing Players
Marriott International Inc
Key Company Facts
Company Description
Snapshot of Competing Players
Ping An Insurance (Group) Company of China, Ltd
Key Company Facts
Company Description
Snapshot of Competing Players
Shanghai Pharmaceuticals Holding Co., Ltd
Key Company Facts
Company Description
Fosun International Ltd - In the News
22-Aug-2025 -First Subject Dosed in the US for a Phase 2 International Clinical Trial of Henlius’ PD-L1 ADC HLX43 for NSCLC
07-Aug-2025 -Henlius to Initiate a Phase 1 Multicenter Study in US of Its PD-L1 ADC HLX43 for the Treatment of Thymic Carcinoma
21-Jul-2025 -Club Med appoints Stephane Maquaire as President and CEO
24-Jun-2025 -Serplulimab Approved in the UK and India for the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
29-May-2025 -Fosun Pharma’s Self-Developed Innovative Drug Luvometinib Tablet Approved in China
10-Apr-2025 -Finloop Becomes a Strategic Enterprise of OASES
19-Mar-2025 -Henlius Receives Orphan-Drug Designation for HLX22 (Innovative anti-HER2 mAb) in the U.S. for Gastric Cancer
19-Feb-2025 -Henlius Bevacizumab Secures First Overseas Approval, Accelerating Henlius' Expansion into Latin American Market
14-Feb-2025 -Fosun Pharma Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation
05-Feb-2025 -Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Fosun International Ltd- Key Deals
31-Jul-2025 - Fosun Tourism Group Signs Syndicated Loan Agreement with Seven International Banks
03-Jul-2025 - Henlius and HanchorBio Collaborate to Develop Novel SIRPα-Fc Fusion Protein, Expanding Tumor Immunotherapy Layout 06-Feb-2025 - Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S
16-Jan-2025 - Fosun International Enters into Strategic Cooperation Agreement with Natixis CIB
Appendix
Definitions
SWOT Analysis
PESTLE Analysis
Value Chain Analysis
ESG Spotlight
Financial Deep Dive
Financial Ratios -
Activity Ratios
Growth Ratios
Leverage Ratios
Liquidity Ratios
Market Ratios
Profitability Ratios
Research Methodology
Disclaimer
Contact Us

Search Inside Report

How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.